AUPH News and Press, Aurinia Pharmaceuticals Inc From 07/15/21

When it comes to finding cheap TSX stocks there are a few things you need to take into consideration, but not necessarily all at once. There might be a cheap share price you want to consider. There could be a future growth opportunity that makes it a discount. Or there could be a pullba...

Earnings season is upon us yet again, and investors are hungry for stocks that could soar. After a year of growth stocks in 2020, investors across the world are greedy for more stocks that could double in a short period. Now here at the Motley Fool, we don’t recommend buying a st...

Investors are always looking for a deal, but it’s getting harder to find. There’s an oil and gas rebound, the pandemic is coming to a close, and economies around the world continue to reopen. The TSX continues to trade at all-time highs, up 250 points in the last month alo...

The TSX continues to climb past record highs this month, passing the 20,000-point mark and not looking back. As the economy continues to recover during the pandemic for a post-pandemic world, there are a few industries that investors should consider. There are still many undervalued sto...

Five patient organizations will receive funds to implement plans aimed at reducing health disparities, connecting people living with systemic lupus erythematosus (SLE) and lupus nephritis (LN) with needed health management resources Aurinia Pharmaceuticals Inc. (NASDAQ: ...

Aurinia Pharmaceuticals' (AUPH) licensing partner, Otsuka Pharmaceutical ((OPEL)) has filed an initial Marketing Authorization Application ((MAA)) for voclosporin for the treatment of lupus nephritis ((LN)) to the EMA.LN is a complication of the autoimmune disease systemic lupus erythematosus...

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the Company) announced today that the Company’s licensing partner, Otsuka Pharmaceutical Europe Ltd. (OPEL), filed an initial Marketing Authorization Application (MAA) for voclosporin for the treatment of lupus nephritis...

The TSX today is filled with expensive stocks. Whereas last year we were in an economic downturn with cheap stocks galore, this year is different. Now the TSX trades at all-time highs, and most stocks are about the same with few Canadian stocks to buy cheap. In fact, the S&P 500 ...

When it comes to Bay Street, and investing in general, patience is what pays. You could look at the one-month performance of TSX stocks and see thousands of dollars lost. Or you could zoom out and see what those same shares have done over the last few years — even decades. People...

Lupkynis (voclosporin) received FDA approval in January 2021. Unwarranted sell-off after 1Q21 earnings release has created a buying opportunity. Anticipated solid Lupkynis revenue in 2Q21 and full year 2021. Doubling of share price achievable within 12 months. For furthe...